Pestalozzi advises Johnson & Johnson on R&D funding collaboration with Royalty Pharma

On 30 March 2026, it has been announced that  Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, entered into a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of USD 500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.

JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune‑mediated diseases.

Pestalozzi advised Johnson & Johnson as to matters of Swiss law of this transaction, alongside Ropes & Gray LLP.

See PR here: Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases | Royalty Pharma

Pestalozzi Attorneys at Law Ltd.
Zurich – Feldeggstrasse 4 | 8008 Zurich | Switzerland | T +41 44 217 91 11
Geneva – Cours de Rive 13 | 1204 Geneva | Switzerland | T +41 22 999 96 00
www.pestalozzilaw.com